{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:49:24Z","timestamp":1775152164382,"version":"3.50.1"},"reference-count":41,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the efficacy and safety of pregabalin monotherapy versus placebo for symptomatic pain relief and improvement of patient global assessment in patients with fibromyalgia (FM) enrolled from countries outside the United States.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This international, multicenter, double-blind, placebo-controlled trial randomly assigned 747 patients with FM to placebo or 300, 450, or 600 mg\/day pregabalin twice daily for 14 weeks. Primary efficacy measures were endpoint mean pain scores and Patient Global Impression of Change (PGIC). Secondary outcomes included assessments of sleep and function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Patients in the 450 mg\/day pregabalin group showed significant improvements versus placebo in endpoint mean pain score (\u22120.56; p = 0.0132), PGIC (73% improved vs 56% placebo; p = 0.0017), and function [Fibromyalgia Impact Questionnaire (FIQ) total score \u22125.85; p = 0.0012]. PGIC was also significant for 600 mg\/day pregabalin (69% improved; p = 0.0227). Results for these endpoints were nonsignificant for pregabalin at 300 mg\/day and for pain and FIQ score at 600 mg\/day. Early onset of pain relief was seen, with separation from placebo detected by Week 1 in all pregabalin groups. All pregabalin doses demonstrated superiority to placebo on the Medical Outcomes Study-Sleep Scale Sleep Disturbance subscale and the Sleep Quality diary. Dizziness and somnolence were the most frequently reported adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Pregabalin demonstrated modest efficacy in pain, global assessment, and function in FM at 450 mg\/day, and improved sleep across all dose levels, but it did not provide consistent evidence of benefit at 300 and 600 mg\/day in this study. Pregabalin was generally well tolerated for the treatment of FM. (Clinical trial registry<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00333866\">NCT00333866<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.110569","type":"journal-article","created":{"date-parts":[[2011,10,2]],"date-time":"2011-10-02T00:26:55Z","timestamp":1317515215000},"page":"2643-2652","source":"Crossref","is-referenced-by-count":72,"title":["An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia"],"prefix":"10.3899","volume":"38","author":[{"given":"LYNNE","family":"PAUER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDREAS","family":"WINKELMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PIERRE","family":"ARSENAULT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANDERS","family":"JESPERSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LAURENCE","family":"WHELAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GARY","family":"ATKINSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TERESA","family":"LEON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BERNHARDT","family":"ZEIHER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"2018112909271683000_38.12.2643.1","unstructured":"Bennett RM . Fibromyalgia. In: Wall PD Melzack R , eds. Textbook of pain. 4th ed. London: Harcourt Publishers, Churchill Livingstone; 1999:579\u2013601."},{"key":"2018112909271683000_38.12.2643.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(03)00035-4"},{"key":"2018112909271683000_38.12.2643.3","first-page":"6","article-title":"Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment","volume":"75","author":"Mease","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"2018112909271683000_38.12.2643.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"2018112909271683000_38.12.2643.5","first-page":"259","article-title":"Prevalence of fibromyalgia: a large-scale European survey: results in France [abstract]","volume":"67","author":"Bannwarth","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909271683000_38.12.2643.6","first-page":"259","article-title":"Prevalence of fibromyalgia: early results in United Kingdom [abstract]","volume":"67","author":"Rou\u00e9-Le Lay","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909271683000_38.12.2643.7","first-page":"259","article-title":"Prevalence of fibromyalgia: a large-scale European survey: results in Germany [abstract]","volume":"67","author":"Spaeth","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909271683000_38.12.2643.8","first-page":"653","article-title":"Prevalence of fibromyalgia and main symptoms assessment in the health care system population of Embu, Sao Paolo, Brazil [abstract]","volume":"66","author":"Assumpc\u00e3o","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2018112909271683000_38.12.2643.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057166"},{"key":"2018112909271683000_38.12.2643.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057166"},{"key":"2018112909271683000_38.12.2643.11","first-page":"617","article-title":"Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study","volume":"20","author":"Cardiel","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909271683000_38.12.2643.12","first-page":"348","article-title":"Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study","volume":"32","author":"Haq","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909271683000_38.12.2643.13","doi-asserted-by":"publisher","DOI":"10.1080\/028134300453340"},{"key":"2018112909271683000_38.12.2643.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065052"},{"key":"2018112909271683000_38.12.2643.15","first-page":"259","article-title":"Prevalence of fibromyalgia: early results in Russia [abstract]","volume":"67","author":"Nasonov","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2018112909271683000_38.12.2643.16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/03009749309095129","article-title":"Fibromyalgia in the adult Danish population: I. A prevalence study","volume":"22","author":"Prescott","year":"1993","journal-title":"Scand J Rheumatol"},{"key":"2018112909271683000_38.12.2643.17","first-page":"594","article-title":"Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach","volume":"31","author":"Senna","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909271683000_38.12.2643.18","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600907949"},{"key":"2018112909271683000_38.12.2643.19","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510026337"},{"key":"2018112909271683000_38.12.2643.20","first-page":"1570","article-title":"The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario","volume":"26","author":"White","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909271683000_38.12.2643.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"2018112909271683000_38.12.2643.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"2018112909271683000_38.12.2643.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.23826"},{"key":"2018112909271683000_38.12.2643.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409066103"},{"key":"2018112909271683000_38.12.2643.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.027"},{"key":"2018112909271683000_38.12.2643.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20983"},{"key":"2018112909271683000_38.12.2643.27","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909271683000_38.12.2643.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.03.013"},{"key":"2018112909271683000_38.12.2643.29","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8"},{"key":"2018112909271683000_38.12.2643.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2018112909271683000_38.12.2643.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"2018112909271683000_38.12.2643.32","doi-asserted-by":"crossref","unstructured":"Guy W . ECDEU assessment manual for psychopharmacology (DHEW Publication No. ADM 76-338). Washington, DC: U.S. Government Printing Office; 1976.","DOI":"10.1037\/e591322011-001"},{"key":"2018112909271683000_38.12.2643.33","unstructured":"Hays RD Stewart AL . Sleep measures. In: Stewart AL Ware JE Jr , eds. Measuring functioning and well-being. Durham, NC: Duke University Press; 1992:235\u20139."},{"key":"2018112909271683000_38.12.2643.34","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"},{"key":"2018112909271683000_38.12.2643.35","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-54"},{"key":"2018112909271683000_38.12.2643.36","unstructured":"Snaith RP Zigmond AS . The Hospital Anxiety and Depression Scale manual. London: NFER Nelson; 1994."},{"key":"2018112909271683000_38.12.2643.37","unstructured":"Steel R Torrie J . Principles and procedures of statistics. New York: McGraw-Hill; 1960."},{"key":"2018112909271683000_38.12.2643.38","unstructured":"Berry D . Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker; 1990."},{"key":"2018112909271683000_38.12.2643.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2018112909271683000_38.12.2643.40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-8-27"},{"key":"2018112909271683000_38.12.2643.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6977.452"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.110569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T22:00:37Z","timestamp":1560722437000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.110569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.3899\/jrheum.110569"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.110569","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}